Innoviva price to book ratio INVA

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026: 1.2×
8-year median: 1.9×
Against its 8-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.2× to 10.1×
Peer median: 2.8×

Innoviva's price to book ratio is 1.2× as of Oct 23, 2026.

That is below its 8-year median of 1.9×, lower than on 98% of days in the last 8 years.

Over that time it ranged from 1.2× in Jul 2026 to 10.1× in Mar 2019.

The median for 10 large drugmakers of a similar size is 2.8×.

Price to book ratio over time

median 1.9×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.2×	1.2×	1.7×
2025	1.5×	1.5×	2.1×
2024	1.6×	1.4×	1.9×
2023	1.6×	1.3×	1.7×
2022	1.4×	1.4×	3.4×
2021	3.0×	1.8×	3.6×
2020	2.6×	2.1×	5.7×
2019	5.4×	4.5×	10.1×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	8.8×	7.4×	12.1×
2013	8.6×	8.6×	39.5×
2012	9.0×	8.5×	199×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

Company	Price to book ratio
INVAInnoviva	1.2×
ANABAnaptysbio	138×
PCRXPacira BioSciences	2.2×
PAHCPhibro Animal Health	4.1×
ANIPANI Pharmaceuticals	2.8×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.4×
HRMYHarmony Biosciences	2.1×
PBHPrestige Consumer Healthcare	1.2×
ABUSArbutus Biopharma	3.2×
NRIXNurix Therapeutics	2.9×
Peer median	2.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Innoviva

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.